Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Core Insights - Jade Biosciences has introduced JADE201, an investigational monoclonal antibody targeting BAFF-R, aimed at improving treatment for autoimmune diseases by extending half-life and enhancing efficacy [1][3][4] Company Overview - Jade Biosciences is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, with a portfolio that includes JADE201 and JADE101 [10] Product Details - JADE201 is designed with a dual mechanism of action, combining enhanced B cell depletion and blockade of BAFF-R signaling, which aims to provide deeper and more durable B-cell depletion with less frequent dosing [2][8] - The product incorporates afucosylation to enhance antibody-dependent cellular toxicity and a clinically validated Fc mutation to increase binding to the neonatal Fc receptor, thereby extending systemic exposure [2][4] Clinical Development - The clinical proof-of-concept for BAFF-R inhibition has been established by ianalumab, which has shown efficacy in multiple autoimmune indications [3] - JADE201 has demonstrated approximately a two-fold increase in half-life compared to ianalumab in non-human primate studies, supporting its potential for improved treatment convenience and efficacy [4] Future Plans - A first-in-human study for JADE201 in patients with rheumatoid arthritis is expected to begin in the first half of 2026, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics [5]